NCT06670352

Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN

A Randomized, Double-blind, and Placebo-controlled Parallel Phase II Clinical Study to Evaluate the Efficacy and Safety of HSK39297 Tablets in Treatment of Patients with Primary IgAN

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Haisco Pharmaceutical Group Co., Ltd. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Evaluate the efficacy and safety of HSK39297 tablets in patients with primary IgAN

Conditions

• IgA Nephropathy (IgAN)

Interventions

Type	Name	Description
DRUG	Placebo	QD or BID, 24-weeks fixed dose.
DRUG	HSK39297 50mgBID	24-weeks fixed dose.
DRUG	HSK39297 100mgBID	24-weeks fixed dose.
DRUG	HSK39297 200mgQD	24-weeks fixed dose.

Timeline

• Start date: 2024-10-12
• Primary completion: 2025-11-23
• Completion: 2026-03-15
• First posted: 2024-11-01
• Last updated: 2024-11-01

Locations

2 sites across 1 country: China